Biogen (NASDAQ: BIIB) reported third-quarter 2021 financial results before the regular market hours on Wednesday. The company reported Q3 revenue of $2.78 billion, down 18% year-over-year and higher than the Wall Street projection. Net income of $4.77 per share was also well above the target that analysts had anticipated.
BIIB shares rose 2% immediately following the announcement. The stock has gained a modest 10% since the beginning of this year.
Prior performance
Most Popular
Shopify (SHOP): This recession-proof stock looks unstoppable. Here’s why
The virus-related movement restrictions have had a complementary effect on the business of Shopify Inc. (NYSE: SHOP), which was already thriving on the widespread cloud adoption and digital shift. The
IPO: Here are the things to know about Fresh Grapes’ market debut
There has been a spurt in the number of food and beverages companies going public lately, but many of them failed to perform as expected in the stock market. Fresh
Hormel Foods (HRL) fine-tunes biz strategy to beat challenges. Is the stock a buy?
For consumer staples companies, rising inflation is probably turning into a bigger challenge than the virus-induced supply chain disruption and store closures. After bettering its position since the early months
